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Abstract
In this study free kappa light chains in cerebrospinal fluid (CSF) were determined both by an affinity mediated capillary blotting 
technique after isoelectric focusing (IEF) in agarose gel and by a quantitative enzyme linked immunosorbent assay (ELISA). The free 
kappa results were compared with the IgG findings in 4 neurological patient groups with a distinct CSF IgG pattern: (1) CSF without 
oligoclonal IgG bands, (2) CSF with serum derived IgG bands, (3) CSF restricted IgG bands and (4) CSF restricted and serum derived 
IgG bands. Oligoclonal free kappa bands are nearly absent in CSF of groups 1 + 2, and present in 88% of group 3 and 84% of group 4 
patients. We could also establish free kappa indices from specimens in the 4 groups in analogy to IgG indices. Group 1 had a median free 
kappa index of 1.1, group 2: 1.0 and groups 3+4: 10.0. The correspondence between immunoblot and index findings for free kappa is 
better than for IgG. Free kappa index is more sensitive but somewhat less specific than IgG index for establishing intrathecal immune 
production.
Keywords: Cerebrospinal fluid; Free kappa light chain; IgG index; Free kappa index
1. Introduction
Several diseases of the nervous system are associated 
with immunological abnormalities in cerebrospinal fluid 
(CSF). Selective increase in the CSF IgG level has been 
observed consistendy in M S and it has become an impor­
tant laboratory test for confirmation of the diagnosis (Poser 
et al., 1983). A selective CSF IgG increase can be estab­
lished by using the IgG Index (Link and Tibbling, 1977), 
formulas for intrathecal produced IgG (Reiber and Felgen- 
hauer, 1987; Ohman et al., 1992) or by detection of CSF 
restricted oligoclonal IgG bands (Walker et al., 1983; 
Luxton et al., 1990).
The IgG finding in MS is nonspecific, as also patients 
with central nervous system (CNS) infections or inflamma­
tory diseases have regularly elevated CSF IgG levels. 
Besides IgG, also selective increase of free kappa and 
lambda light chains (free kappa, free lambda) in CSF has
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been found in MS and other neuro-immunological disor­
ders (Fagnart et a l, 1988; Rudick et al., 1986; Gallo et al, 
1989; Decarli et al., 1987). CSF oligoclonal free kappa 
bands in MS have been observed with about the same 
frequency as that for CSF oligoclonal IgG bands (Sindic 
and Laterre, 1991a). Free light chain determination in CSF 
also has relevance for the diagnostics of patients with early 
M S (Lolli et al., 1991) and the presence of CSF free light 
chains correlates significantly with recent demyelinadng 
activity in MS (Vakaet and Thompson, 1985; Bracco et al., 
1987). From these studies it is clear that intrathecally 
produced CSF IgG is mostly accompanied by intrathecally 
produced CSF free light chains and free light chain detec­
tion is a complementary, although optional, test to estab­
lish a laboratory-supported diagnosis (Sindic and Laterre, 
1991b). However, in all publications the detection limit for 
free light chain determination is too high to measure CSF 
levels in ‘normal* patients. Furthermore, the coincidence 
of free light chain levels with oligoclonal free light chains 
in CSF and the relation between IgG- and free light chain 
findings in CSF are not systematically investigated.
Therefore, we developed a sensitive E L IS A  test for
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Table 2
Median values and ranges of immunological parameters in CSF and serum in the 3 patient groups
Parameter Unit Group I: 
IgG normal 
(n =  37)
Group 2: 
IgG mirror 
(n =  31)
Group 3 + 4 :  
IgG restricted 
(plus) (n =  38)
Median (Range) Median (Range) Median (Range)
CSF IgG m g /l 21 (9-51) 42 (10-150) 35 (12-130)
CSF free kappa Mg/1 25 (5.8-85) 50 (8.8-410) 330 (20- 2100)
Serum IgG g/1 11 (6.0- 21) 11 (4.1-20) 10 (4.9-23)
Serum free kappa m g /l 4.2 (2.7-9.5) 6.1 (1.6-23) 5.0 0 .2 -1 8 )
Ratio albumin X 10-3 4.0 (2.5-10) 7.7 (3.0-49) 5.2 (2.4-19)
Ratio IgG X 1( T 3 1.7 (1.1-4.4) 3.6 (1.3-35) 3.9 (1.4-11)
Ratio free kappa X 10~3 5.0 ( 1.2- 11) 9.6 (3.3-55) 68 (5.6-330)
Index IgG --- 0.46 (0.42-0.58) 0.46 (0.36-0.71) 0.67 (0.44-2.9)
Index free kappa — 1.1 (0.5-2.9) 1.0 (0.5-4.4) 10 (1.6-89)
2.2.7. Free kappa immunoblot
For oligoclonal free kappa the same method as for 
oligoclonal IgG was used with minor modifications. A l­
ways 10 / i \  unconcentrated (or diluted) CSF and 7.5 j j l I  
(1:100) diluted serum were applied upon the agarose gel. 
Instead of passive protein transfer affinity-mediated capil­
lary blotting was performed. The NC membrane was incu­
bated overnight with rabbit antihuman free kappa, diluted 
(1:500) with PBS (code A10G Dakopatts, Copenhagen).
The NC membrane was washed in PBS and blocked 
during 1 h in 3% bovine serum albumin/PBS and again 
washed in PBS. The focused proteins in agarose were 
blotted onto the NC membrane for 30 min. After blocking 
of the NC membrane for 60 min in 2% milk powder in 
0.15 M  NaCl the membrane was incubated with (1:500) 
diluted rabbit antihuman total kappa, HRP labelled, in 
0.2% milk powder/NaCl for 2 h (code P129 Dakopatts, 






□ CSF normal 
A CSF mirror
Q-albumin
Fig. 2. Relation between Q albumin ( X 10 3) and Q free kappa ( X 10 3) in patients of group (3 + 4) (top) and in patients of groups 1 and 2 (bottom).- 3
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2.2.2. Free kappa ELISA
Free kappa light chains were measured by a solid phase 
‘sandwich’ EL ISA . Microtiter plates were coated overnight 
with 200 fA (1:1000) diluted rabbit antihuman free kappa 
(Dakopatts, code A 100, Copenhagen). Reagents are the 
same as in an earlier described method (Haraldson et al., 
1991). After washing, blocking with 2% bovine albumin 
and washing 100 pX native CSF and (1:10 and 1:100) 
diluted CSF and corresponding serum (1:2000) diluted 
were incubated 90 min at 37°C. After washing, 100 /j l \ 
HRP conjugated rabbit antihuman total kappa (1:1000) 
diluted (Dakopatts, code P I29, Copenhagen) was incu­
bated 90 min at 37°C. Color development was performed 
with OPD-re agent. Standard curves were performed with 
dilutions of an oligoclonal free kappa pool CSF. The 
pooled CSF was left 2 days at 4°C, centrifuged and filtered 
through a 0.2 pan filter and divided in aliquots of 0.5 ml 
and stored at — 70°C, The CSF pool was calibrated on a 
commercial purified free kappa standard (2.7 mg/ml, 
Tago, Burlingame, CA, USA). CSF pool is 100%. We 
used always 9 standard dilutions (from 0.1% to 2% of the 
CSF pool). 1% CSF pool solution corresponds with 14.6 
g/i Tago free kappa light chain concentration. With help 
of the CSF pool standards the reproducibility of the assay 
was much better than with Tago standards. The lower limit 
of sensitivity is 2 /xg/1. To evaluate intra-assay precision, 
we studied two diluted CSF samples containing 3 and 7 
/xg/1 free kappa, repeating the assays 20 times on the 
same day. The coefficient of variation (CV) was respec­
tively 6.1% and 2.9%. The inter assay precision was 
determined by daily assay of 1 CSF sample, containing 3 
jag/1 free kappa for 9 days. The CV was 8.1%. Concentra­
tions remained stable during storage at -~70°C and — 20°C 
for 3 months. To test the specificity of the assay we used 
CSF specimens with a high free kappa level in our EL ISA  
test. In a modified EL ISA  test we used in stead of HRP 
conjugated rabbit antihuman total kappa as second anti-
Index - free kappa
100
Groupnr. 1 2 3 + 4
Fig. 4. Distribution of index free kappa values measured in patients of 
groups 1, 2 and (3 +4), The line represents the upper limit ( + 2 SD) of 
the control group.
body, HRP conjugated goat antihuman IgG (Fc), gamma 
chain specific. The free kappa positive specimens all gave 
a negative reaction with this second antibody. This nega­
tive reaction excludes a cross reaction of intact IgG 
molecules with rabbit antihuman free kappa.
3* Results
3 J . Free kappa investigation with immunoblot
All CSF and serum samples were tested for the pres­
ence of oligoclonal free kappa bands. Fig. 1 shows exam­
ples of immunoblot findings in patients out of the 4 groups 
and also in one patient with an IgG kappa paraproteinemia. 
There is no cross reaction of antibodies to oligoclonal free 
kappa with oligoclonal IgG molecules. Table 1 summa­













Fig. 3. Relation between intrathecal CSF IgG (mg/1) and CSF free kappa ( ¡lg/1) in patients of group (3 +  4, CSF restricted plus),
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groups. Generally, oligoclonal free kappa bands are very 
scarce in serum: the 6 specimens from group 2 with 
positive serum free kappa had an identical free kappa 
pattern in serum and CSF. In patients with local IgG 
synthesis (groups 3 + 4), CSF oligoclonal free kappa is 
frequent (88% in group 3 and 84% in group 4), The free 
kappa oligoclonal pattern was always different from the 
IgG oligoclonal pattern in all positive specimens.
5.2. Free kappa investigation with ELISA
In a number of patients in each group we measured in 
CSF and serum also the quantitative levels of free kappa, 
IgG and albumin, and calculated ratios and indices. We 
selected 37 patients from group 1, 31 patients from group 
2 and 38 patients from groups 3 4-4. The results of the 
free kappa immunoblots in groups 3+ 4  were not differ­
ent. Therefore we handled groups 3 + 4 as one group. In 
Table 2 we present the median values and the ranges of the 
immunological parameters for the 3 groups. The median 
serum levels of free kappa in the 3 groups are comparable 
but the median CSF levels are different: 25, 50 and 330 
/xg/I for groups 1, 2 and (3 + 4 ) respectively, Further­
more, the median level of index free kappa in group 
(3 + 4) (local IgG synthesis) is 10-times higher than the 
median level of index free kappa of groups 1 and 2 (no 
local IgG synthesis). A ll 37 patients in group 1 had normal 
white cell number in CSF, an albumin ratio ^  10 X 10-3, 
no oligoclonal IgG bands and normal IgG index. The 
mean + SD of the free kappa index for this ‘IgG-normar 
group is 1.3 ±0.5. Therefore, we considered patients of 
group 1 as a nonimmunological ‘control group’ for free 
kappa index with 2 SD limits: 0.3-2.3.
In Fig. 2, the relation between ratio serum/CSF (Q) 
albumin and Q free kappa is presented for the 3 groups. 
The correlation coefficient between Q albumin and Q free 
kappa is 0.64 for group l t 0.49 for group 2 and —0.064 
for group (3 + 4). The correlation coefficient between 
intrathecal CSF IgG and CSF free kappa is 0.91 (Fig. 3). 
In Fig. 4 the free kappa indices for the 3 patient groups are 
presented.
Table 4









1 Normal 37 0 2
2 Mirror 31 2 3
3 + 4 Restricted (plus) 38 26 34
33. Correspondence between immunoblot and index find­
ings
4
In Table 3 we present the results of immunoblots and 
indices of free kappa and IgG in the 3 patient groups. In 
the total group of 106 patients the index and immunoblot 
correspond in 102 patients for free kappa (96%) and in 92 
patients for IgG (87%). In Table 4 we present the results of 
IgG- and free kappa indices in the 3 patient groups. Based 
on the acceptance that IgG isoelectric focusing is the ‘gold 
standard’ for indication of an intrathecal IgG production, it 
can be concluded that for free kappa index 4 false nega­
tives and 5 false positives were found and for IgG index 
12 false negatives and 2 false positives.
4. Discussion
A selective increase in CSF of free kappa has been 
found in patients with M S and in patients with infections 
of the CNS. The incidence of CSF oligoclonal free kappa 
in neuroimmunological disorders is not systematically 
studied. W e investigated the coincidence of free kappa and 
IgG oligoclonal bands in CSF and serum in 4 neurological 
patient groups. Generally, free kappa bands are very scarce 
in serum. In 88% of patients with CSF IgG restricted 
bands (group 3) and in 84% patients with CSF IgG re­
stricted and additional bands (group 4), CSF free kappa 
bands are present. These findings can confirm observations 
from other studies that CSF oligoclonal free kappa bands 
can be demonstrated in a high percentage in patients with 
local IgG synthesis (Sindic and Laterre, 1991b; Gallo et
Table 3
Correspondence of immunoblot and index results of free kappa and IgG in the three patient groups
Group Oligoclonal IgG pattern Number Free kappa IgG
Immunoblota: + + — — + + — —
Index b: + — + — + — + —
1 Normal 37 0 1 2 34' 0 0 0 37
2 Mirror 31 3 I 0 27 0 0 2 29
3 + 4 Restricted (plus) 38 34 0 0 4 26 12 0 0
Total 106 37 2 2 65 26 12 2 66
a + , positive; —, negative. 
h + , increased; —, normal.
K J H I ¿inters el a I. /  Journal of Neuroimmunology 62 (1995) 19-25
uL 1989; Lolli et a!.. 1991). In patients with identical IgG 
bands in CSF and serum (group 2), CSF iree kappa bands 
are only present in 8%. From these data it is obvious that 
in contrast to intraiheeally produced oligotional IgG, sys- 
tcmically produced oligoclonal IgG is seldom accompa­
nied with oligoclonal free kappa. This phenomenon can 
probably he explained by the rapid removal of these small 
free kappa proteins from blood to urine as is found for 
Bence Jones proteinuria in patients with myeloma. In case 
a laboratory receives only CSF and no serum of a patient it 
is more conclusive to perform both oligoclonal IgG and 
oligoclonal free kappa isoelectric focusing. When both 
investigations arc positive, this is a strong indication for 
intrathecal IgG production. When oligoclonal IgG is posi­
tive and oligoclonal free kappa is negative, this is a strong 
indication for systemic IgG production.
With respect to the quantitative levels, in patients with­
out immunological CNS disturbances, the levels in CSF of 
tree kappa are mostly below the detection limit of the 
assay in literature (Fagnart et al., 1988; Lolli et al., 1991; 
Rudick et al., 1986). We have developed a sensitive 
method in order to determine ‘normal* CSF free kappa 
levels. Our median free kappa serum level (4.2 mg/1) is 
nearly 3-times higher than the value of 1.58 mg/1 reported 
by Fagnart et al. (1988), comparable with the value of 3.36 
mg/1 reported by Rudick et al. (1986), and 4-times lower 
than the value reported by Sollink (1975). Absolute levels 
of free light chains in body fluids are difficult to compare 
owing to both the differences in specific anti sera and the 
absence of a valid free kappa light chain standard. The use 
of an index mitigates the problem of an appropriate stan­
dard. As free light chains are smaller molecules than 
albumin, theoretically the index must be higher than 1,0 
since the filtration process of the blood CSF barrier is size 
dependent and proportional for free light chains. The me­
dian index of 1.1 for free kappa and the relationship 
between Q albumin and Q free kappa for the control group 
can confirm the validity of the use of a free kappa index 
for establishing intrathecal free kappa production.
Based on the acceptance that IgG isoelectric focusing is 
the 'gold standard’ for indication of intrathecal IgG pro­
duction, we can establish for free kappa index a sensitivity 
of 90% and a specificity of 93%, and for IgG index a 
sensitivity of 6K% and a specificity of 97%. The patho­
physiological significance of intrathecal production of free 
light chains remains obscure. Their presence is not due to 
local degradation of immunoglobulins but excess of free 
light chains is likely a marker of the ongoing intrathecal 
humoral immune response. In conclusion:
• CSF oligoclonal free kappa is observed with about the 
same frequency as that for CSF restricted oligoclonal 
IgG (groups 3 and 4 in Table 1).
■ In case a laboratory receives only CSF and no serum of 
a patient oligoclonal free kappa investigation is more 
conclusive than oligoclonal IgG.
The correspondence between immunoblot and index 
findings for free kappa is better than for IgG (Table 3). 
Free kappa index is more sensitive but somewhat less 
specific than IgG index for establishing intrathecal im­
mune production (Table 4).
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